Various N'-[3-(4-substituted alkyl/aryl thiaiazolidin-2-ylidene]-4-hydroxy benzohydrazide (4.a -i) and N'-[-(3,4-disubstituted)-1,3-thiazolidin-2ylidene)]-4-hydroxybenzohydrazide from (5.a -i) to (10.a -i) were synthesized using appropriate synthetic route. The entire test compounds (4.a -i) and compounds from (5.a -i) to (10.a -i) were assayed in vitro against H 37 Rv strain of M. tuberculosis. The minimum inhibitory concentration (MIC) was determined for test compounds and for reference standards. The test compounds showed significant antimycobacterial activity against the microbial strains used, when tested in vitro. In general, p-hydroxybenzohydrazide ring and substituted thiazoline ring are essential for antimicrobial activity. Among the compounds tested, compounds 5.i, 6.f, 7.d, 8.g and 9.f were found to be most potent. The test compounds were found to be nontoxic up to a dose level of 1000 mg/mL. All compounds were then subjected for 3D-QSAR studies. 3D-QSAR study based on the principal of alignment of pharmacophoric features by Schrodinger PHASE module. The 3D-QSAR study allowed us to confirm the preferential binding mode of p-hydroxybenzohydrazide inside the active site.